Table 2.
Discrimination of samples in the test cohort according to 7-signal proteomic model.
| Number of cases analyzed | Number of correctly assigned cases (%) | 95% C.I.* (%) | |
|---|---|---|---|
| All samples | 129 | 112 (86.8) | 79.7–92.1 |
| Healthy subjects | 67 | 60 (89.6) | 79.7–95.7 |
| Pancreatic ductal adenocarcinoma (ACCH) | 16 | 13 (81.3) | 54.4–96.0 |
| Pancreatic ductal adenocarcinoma (NUH) | 30 | 25 (83.3) | 65.3–94.4 |
| Acute pancreatitis (NUH) | 2 | 0 (0) | 0–84.2 |
| Chronic pancreatitis (NUH) | 11 | 11 (100) | 71.5–100 |
| Autoimmune pancreatitis (NUH) | 3 | 3 (100) | 29.2–100 |
| Clinical stage of pancreatic ductal adenocarcinoma patients at ACCH | |||
| 0/I | 0 | NA | NA |
| II | 1 | 0 (0) | 0–97.5 |
| III | 3 | 3 (100) | 29.2–100 |
| IVa | 4 | 2 (50) | 6.8–93.2 |
| IVb | 8 | 8 (100) | 63.1–100 |
| Clinical stage of pancreatic ductal adenocarcinoma patients at NUH | |||
| 0/I | 1 | 0 (0) | 0–97.5 |
| II | 6 | 5 (83.3) | 35.9–99.6 |
| III | 13 | 11 (84.6) | 54.6–98.1 |
| IVa | 10 | 9 (90) | 55.5–99.7 |
| IVb | 0 | NA | NA |
*95% confidence interval
NA: not available.